35/3,AB/2 (Item 2 from file: 348)
DIALOG(R)File 348:European Patents
(c) 2000 European Patent Office. All rts. reserv.

00508279
ORDER fax of complete patent from Dialog SourceOne. See HELP ORDER 348
VACCINES
IMPFSTOFFE
VACCINS
PATENT ASSIGNEE:
EVANS MEDICAL LIMITED, (1946510), Evans House, Regent Park, Kingston Road , Leatherhead, Surrey KT22 7PQ, (GB), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
FORD, Martin, James, The Wellcome Foundation Limited Langley Court, Beckenham Kent BR3 3BS, (GB)
LEGAL REPRESENTATIVE:
Woods, Geoffrey Corlett et al (48721), J.A. KEMP & CO. 14 South Square Gray's Inn, London WC1R 5LX, (GB)
PATENT (CC, No, Kind, Date): EP 546036 A1 930616 (Basic)
EP 546036 B1 971015
WO 9203162 920305
APPLICATION (CC, No, Date): EP 91915775 910823; WO 91GB1426 910823
PRIORITY (CC, No, Date): GB 9018690 900824
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-039/145; A61K-009/127;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9710W2	284
CLAIMS B	(German)	9710W2	287
CLAIMS B	(French)	9710W2	315
SPEC B	(English)	9710W2	4938
Total word count - document A			0
Total word count - document B			5824
Total word count - documents A + B			5824

35/3,AB/3 (Item 3 from file: 348)
DIALOG(R)File 348:European Patents
(c) 2000 European Patent Office. All rts. reserv.

00489393
ORDER fax of complete patent from Dialog SourceOne. See HELP ORDER 348
Liposomal compositions and processes for their production
Liposomale Mittel sowie Verfahren zu deren Herstellung
Compositions liposomales et leurs procedes de preparation
PATENT ASSIGNEE:
INSTITUTO NACIONAL DE ENGENHARIA E TECNOLOGIA INDUSTRIAL, (1333511), Estrada do Paco do Lumiar, 1699 Lisboa Codex, (PT), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Meirinhos da Cruz, Maria Eugenia, Rua Maestro Raul Ferrao 43, P-1500 Lisboa, (PT)
Santana Jorge, Joao Carlos, Rua Bernardo Santareno, Lote C-22-6oC, Miratejo, P-2880 Almada, (PT)
Figueria Martins, Maria Barbara dos Anjos, Rua Luis Pedrosa de Barros, 2-2o-A., P1400 Lisboa, (PT)
Guilherme Gaspar, Maria Manuela de Jesus, Praca Dr. Ernesto Roma 8-3oA, P-1900 Lisboa, (PT)
Esteves Simoes, Aida da Conceicao, Rua da Quinta das Palmeiras, 100r/c

Esq., P-2780 Oeiras, (PT)
Perez-Soler, Roman, 2904 Rice Boulevard, Houston, Texas 77005, (US)
LEGAL REPRESENTATIVE:
Powell, Stephen David et al (52311), WILLIAMS, POWELL & ASSOCIATES 34 Tavistock Street, London WC2E 7PB, (GB)
PATENT (CC, No, Kind, Date): EP 485143 A1 920513 (Basic)
EP 485143 B1 971217
APPLICATION (CC, No, Date): EP 91310180 911104;
PRIORITY (CC, No, Date): PT 95812 901106; PT 96037 901128
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS: A61K-009/127; A61K-038/46;

ABSTRACT EP 485143 A1
Liposomal compositions are described containing an enzyme having L-Asparaginase activity characterized by having a protein/lipid ratio of at least 30 (mu)g/ (mu)mol, the size of liposomes being up to 1000 nm. The enzymatic activity is located in the aqueous or lipid phase or both. The compositions are prepared by forming multilamellar liposomes containing the enzyme and subjecting the liposomes to lyophilization, rehydration and extrusion under pressure.
ABSTRACT WORD COUNT: 68

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9712W2	400
CLAIMS B	(German)	9712W2	396
CLAIMS B	(French)	9712W2	418
SPEC B	(English)	9712W2	4294
Total word count - document A			0
Total word count - document B			5508
Total word count - documents A + B			5508

35/3,AB/4 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.

03037458
Utility
FUSOGENIC LIPOSOMES THAT ARE FREE OF ACTIVE NEURAMINIDASE

PATENT NO.: 5,985,318
ISSUED: November 16, 1999 (19991116)
INVENTOR(s): Ford, Martin James, Beckenham, GB (United Kingdom)
ASSIGNEE(s): Burroughs Wellcome Co , (A U.S. Company or Corporation), Research Triangle Park, NC (North Carolina), US (United States of America)
[Assignee Code(s): 12720]
APPL. NO.: 8-406,101
FILED: March 16, 1995 (19950316)
PRIORITY: 9018690, GB (United Kingdom), August 24, 1990 (19900824)

This is a continuation of application Ser. No. 07-974,589, filed Feb. 22, 1993 now abandoned.

FULL TEXT: 747 lines

ABSTRACT

Liposomes which have present on their surface a polypeptide capable of binding to a mucosal cell surface of a human or animal and which are substantially free of active neuraminidase are useful as **vaccines** .

35/3,AB/5 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02813234

Utility
METHODS FOR INCREASING THE CIRCULATION HALF-LIFE OF PROTEIN-BASED THERAPEUTICS
[Administering liposome and antineoplastic agent to suppress immune response]

PATENT NO.: 5,780,054
ISSUED: July 14, 1998 (19980714)
INVENTOR(s): Tardi, Paul G., Richmond, CA (Canada)
Swartz, Erik, Vancouver, CA (Canada)
Bally, Marcel B., Bowen Island, CA (Canada)
Cullis, Pieter R., Vancouver, CA (Canada)
ASSIGNEE(s): University of British Columbia, (A Non-U.S. Company or Corporation), CA (Canada)
[Assignee Code(s): 11738]
APPL. NO.: 8-588,014
FILED: January 17, 1996 (19960117)

FULL TEXT: 944 lines

ABSTRACT

Methods of increasing the circulation half-life of protein-based therapeutics in a host, the methods comprising: (a) administering to the host an amount of a first liposome formulation comprising liposomes and an antineoplastic agent; and (b) administering to the host a second formulation comprising the protein-based therapeutic, wherein the amount of the first liposome formulation is sufficient to suppress an immune response to the protein-based therapeutic of the second formulation, thereby increasing the circulation half-life of the protein-based therapeutic.

35/3,AB/10 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02542782

Utility
PARTICLES, METHOD OF PREPARING SAID PARTICLES AND USES THEREOF

PATENT NO.: 5,531,925
ISSUED: July 02, 1996 (19960702)
INVENTOR(s): Landh, Tomas, Lund, SE (Sweden)
Larsson, Kare, Bjarred, SE (Sweden)
ASSIGNEE(s): GS Biochem AB, (A Non-U.S. Company or Corporation), Malmo, SE (Sweden)
[Assignee Code(s): 39131]
EXTRA INFO: Assignment transaction [Reassigned], recorded February 6, 1997 (19970206)
APPL. NO.: 8-211,293
FILED: April 11, 1994 (19940411)
PCT: PCT-SE92-00692 (WO 92SE692)
Section 371 Date: April 11, 1994 (19940411)
Section 102(e) Date: April 11, 1994 (19940411)
Filing Date: October 02, 1992 (19921002)
Publication Number: WO93-06921 (WO 936921)
Publication Date: April 15, 1993 (19930415)
FULL TEXT: 1729 lines

ABSTRACT

Particles, especially colloidal particles, comprising an interior phase of a non-lamellar reversed cubic, intermediate or hexagonal liquid crystalline phase, or a homogeneous L3 phase, and a surface phase of a lamellar crystalline or liquid crystalline phase, or an L3 phase. A method of preparing such particles by creating a local dispersible phase, within the homogeneous phase, preferably by means of a fragmentation agent, and fragmentating the homogeneous phase so as to form said surface phase. Several medical as well as non-medical uses of the particles referred to, e.g. as an antigen-presenting system, as a delivery system for anticancer, antifungal and antimicrobial drugs, and as carriers of nucleic acids or nucleotides.
?

40/3,AB/1 (Item 1 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2000 The Dialog Corp. All rts. reserv.

01089317

Utility
VIRAL LIPOSOME PARTICLE
[COMPRISING AN INFLUENZA VIRUS, A PHOSPHATIDE, AND A FATTY ACID AMINE]

PATENT NO.: 4,201,767
ISSUED: May 06, 1980 (19800506)
INVENTOR(s): Fullerton, Wardle, King of Prussia, PA (Pennsylvania), US (United States of America)
Wolanski, Bohdan, Norristown, PA (Pennsylvania), US (United States of America)
ASSIGNEE(s): Merck & Co Inc , (A U.S. Company or Corporation), Rahway, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 54136]
APPL. NO.: 5-958,778
FILED: November 08, 1978 (19781108)

FULL TEXT: 222 lines

ABSTRACT

The outer membrane of influenza virus is attached to a liposome by two different techniques. In addition, one of the techniques allows the entrapment of intact virus, usually one virus per liposome. The techniques can be performed with either influenza virus A or B.

40/3,AB/2 (Item 2 from file: 653)
DIALOG(R)File 653:US Patents Fulltext
(c) format only 2000 The Dialog Corp. All rts. reserv.

01086974

Utility
LIPOSOME PARTICLE CONTAINING VIRAL OR BACTERIAL ANTIGENIC SUBUNIT

PATENT NO.: 4,199,565
ISSUED: April 22, 1980 (19800422)
INVENTOR(s): Fullerton, William W., King of Prussia, PA (Pennsylvania), US (United States of America)
ASSIGNEE(s): Merck & Co Inc , (A U.S. Company or Corporation), Rahway, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 54136]
APPL. NO.: 6-24,144
FILED: March 26, 1979 (19790326)

FULL TEXT: 203 lines

ABSTRACT

Subunit viral or bacterial antigens are incorporated into liposomes containing a positively charged amino-containing surfactant. The resulting complex is antigenically more active than the free antigen.

40/3,AB/3 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02359210

Utility
N-[.OMEGA.,(.OMEGA.-1)-DIALKYLOXY]- AND N-[.OMEGA.,(.OMEGA.-1)-DIALKENYLOXY]-ALK-1-YL-N,N,N,-TETRASUBSTITUTED AMMONIUM LIPIDS AND USES THEREFOR
[Drug delivery, DNA transfection]

PATENT NO.: 5,366,737
ISSUED: November 22, 1994 (19941122)
INVENTOR(s): Eppstein, Deborah A., Menlo Park, CA (California), US (United States of America)
Felgner, Philip L., Los Altos, CA (California), US (United States of America)
Gadek, Thomas R., Oakland, CA (California), US (United States of America)
Jones, Gordon H., Cupertino, CA (California), US (United States of America)
Roman, Richard B., Fairhope, AL (Alabama), US (United States of America)
ASSIGNEE(s): Syntex (USA) Inc, (A U.S. Company or Corporation), Palo Alto, CA (California), US (United States of America)
[Assignee Code(s): 82370]
APPL. NO.: 8-15,738
FILED: February 10, 1993 (19930210)

RELATED APPLICATIONS

This is a division of allowed copending application Ser. No. 07-614,412, filed Nov. 16, 1990, now U.S. Pat. No. 5,208,036; which is a division of Ser. No. 07-524,257, filed May 15, 1990, now U.S. Pat. No. 5,049,386; which is a division of Ser. No. 07-428,815, filed Oct. 27, 1989, now U.S. Pat. No. 4,946,787; which is a division of Ser. No. 07-114-809, filed Oct. 29, 1987, now U.S. Pat. No. 4,897,355; which is a continuation-in-part of Ser. No. 06-877,916, filed Jun. 24, 1986, now abandoned; which is a continuation-in-part of Ser. No. 06-689,407, filed Jan. 7, 1985, now abandoned; all incorporated herein by reference.

FULL TEXT: 2799 lines

ABSTRACT

This invention relates to compounds of the formula

or an optical isomer thereof wherein R sup 1 and R sup 2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R sup 3, R sup 4 and R sup 5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R sup 3, R sup 4, and R sup 5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.
?

5/9/1
DIALOG(R)File 155:MEDLINE(R)

09893104 99109162
DNA vaccines: **vector design, delivery, and antigen presentation.**
Feltquate DM
Department of Pathology, University of Massachusetts Medical School, Worcester 01655, USA. david.feltquate@ummed.edu
J Cell Biochem Suppl (UNITED STATES) 1998, 30-31 p304-11, ISSN 0733-1959 Journal Code: K8K
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
JOURNAL ANNOUNCEMENT: 9906
Subfile: INDEX MEDICUS
Inoculations with antigen-expressing plasmid DNAs (**DNA vaccines**) in the production of protective immune responses. Since the initial development of **DNA vaccines** more than 5 years ago, major strides have been made in the design of efficient **vaccine** vectors and in the process of **vaccine** delivery. However, many questions remain regarding the mechanism of cellular **transfection** and in the development of immune responses. This **review** addresses functional aspects of **DNA vaccines** , including vector design and delivery, as well as cellular **transfection** and antigen presentation. (39 Refs.)
Tags: Animal; Human
Descriptors: Antigen Presentation; *Drug Delivery Systems--Methods--MT; *Genetic Vectors--Administration and Dosage--AD; *Genetic Vectors --Chemical Synthesis--CS; * **Vaccines , DNA** --Chemical Synthesis--CS; * **Vaccines , DNA** --Genetics--GE; Drug Design; Genetic Engineering--Methods --MT
CAS Registry No.: 0 (Genetic Vectors); 0 (Vaccines, DNA)

5/9/3
DIALOG(R)File 155:MEDLINE(R)

09561750 98281071
Genetic vaccines: strategies for optimization.
Gregoriadis G
Centre for Drug Delivery Research, The School of Pharmacy, London, UK. Gregoriadis@cua.ulsop.ac.uk
Pharm Res (UNITED STATES) May 1998, 15 (5) p661-70, ISSN 0724-8741 Journal Code: PHS
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
JOURNAL ANNOUNCEMENT: 9809
Subfile: INDEX MEDICUS
Vaccination with attenuated or killed microbes, purified or recombinant subunit proteins and synthetic peptides is often hampered by toxicity, the presence of infectious agents, weak immune responses and prohibiting costs, especially in the developing world. Such problems may be circumvented by genetic immunization which has recently emerged as an attractive alternative to conventional **vaccines** . Numerous studies have already shown that immunization of experimental animals with plasmid **DNA** encoding antigens from a wide spectrum of bacteria, viruses, protozoa and cancers leads to protective humoral and cell-mediated immunity. This **review** deals with the background and progress made so far with **DNA vaccines** and their theoretical and practical advantages as well as potential risks, discusses proposed mechanisms of **DNA transfection** of cells and induction of immune responses to the produced **vaccine** antigen, and evaluates strategies for the control and optimization of such responses. (79 Refs.)
Tags: Animal; Human
Descriptors: Antigens, Bacterial--Genetics--GE; *Antigens, Viral --Genetics--GE; *Immunization--Methods--MT; *Plasmids--Therapeutic Use--TU; * **Vaccines , DNA** --Administration and Dosage--AD; Injections,

Intramuscular; Liposomes--Immunology--IM; Macaca mulatta; Mice; Plasmids --Genetics--GE; Plasmids--Immunology--IM; **Transfection** ; **Vaccines, DNA --A** dverse Effects--AE
CAS Registry No.: 0 (Antigens, Bacterial); 0 (Antigens, Viral); 0 (Liposomes); 0 (Plasmids); 0 (Vaccines, DNA)

5/9/4
DIALOG(R)File 155:MEDLINE(R)
(c) format only 1999 Dialog Corporation. All rts. reserv.

09388760 98091727
DNA **cancer** vaccines: **a gene gun approach.**
Mahvi DM; Sheehy MJ; Yang NS
Department of Surgery, University of Wisconsin School of Medicine, Madison, USA.
Immunol Cell Biol (AUSTRALIA) Oct 1997, 75 (5) p456-60, ISSN 0818-9641 Journal Code: GH8
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
JOURNAL ANNOUNCEMENT: 9804
Subfile: INDEX MEDICUS
A wide variety of approaches, all using gene transfer, have been tested experimentally as alternative means to vaccinate against cancer, either prophylactically or therapeutically. These include both ex vivo and in vivo gene transfer to tumour and/or non-tumour cells, using both viral and non-viral vectors. The transferred DNA has varied widely as well, including genomic or cDNA encoding tumour-associated or oncofoetal antigens, cytokines, histocompatibility molecules, and costimulatory molecules. Several of these approaches have been applied in human clinical trials. This **review** summarizes those approaches, then compares and evaluates various methods using cytokine DNA in conjunction with autologous tumour cells, with particular emphasis on particle-mediated gene transfer via a gene gun. Finally, prospects and needs for further development are discussed. (34 Refs.)
Tags: Animal; Human
Descriptors: Cancer Vaccines; *Neoplasms--Therapy--TH; **Vaccines , DNA** ; Cancer Vaccines--Chemical Synthesis--CS; Cancer Vaccines--Therapeutic Use--TU; Cytokines--Genetics--GE; Gene Therapy--Methods--MT; Gene Transfer; Granulocyte-Macrophage Colony-Stimulating Factor--Genetics--GE; Neoplasms --Genetics--GE; **Transfection** --Methods--MT; **Vaccines , DNA** --Chemical Synthesis--CS; **Vaccines , DNA** --Therapeutic Use--TU
CAS Registry No.: 0 (Cancer Vaccines); 0 (Cytokines); 0 (Vaccines, DNA); 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
?

8/S36,576 DIALOG

Set	Items	Description
S1	80	AU="HAENSLER J" OR AU="HAENSLER J L" OR AU="HAENSLER J." OR AU="HAENSLER JEAN" OR AU="HAENSLER JEAN-PIERRE"
S2	60	AU="TRANNOY E" OR AU="TRANNOY E." OR AU="TRANNOY EMANUELLE" OR AU="TRANNOY EMMANUELLE"
S3	169	AU="RONCO J" OR AU="RONCO J J" OR AU="RONCO J R" OR AU="RONCO J." OR AU="RONCO J.J." OR AU="RONCO JJ" OR AU="RONCO JORGE" OR AU="RONCO JR"
S4	296	S1 OR S2 OR S3
S5	555042	ADJUVANT? ? OR VACCINE? ?
S6	81	S4 AND S5
S7	17	S6 NOT PY>1994
S8	10	RD (unique items)
S9	238122	ADJUVANT? ?
S10	2	S8 AND S9
S11	343775	VACCINE? ?
S12	0	S10 AND S11
S13	14338	AMPHIPATHIC
S14	58556	LIPOPHILIC
S15	81383	STEROL
S16	228	CARBOMYL
S17	243499	CATIONIC
S18	0	S13 AND S14 AND S15 AND S16 AND S17
S19	26855	S9 AND S11
S20	407096	CHOLESTEROL
S21	729	S19 AND S20
S22	1278198	AMMONIUM OR AMINE
S23	349	S21 AND S22
S24	0	S16 AND S23
S25	820	CARBOMOYL
S26	0	S23 AND S25
S27	27735	CHOLESTERYL?
S28	0	?CARBOMYL
S29	0	S28(W)CHOLESTEROL
S30	1	DIOLEOYLPHOSPHATIDYETHANOLAMINE
S31	1839	DIOLEOYLPHOSPHATIDYLCHOLINE
S32	1840	S30 OR S31
S33	2	S25(W)S20
S34	15	S11 AND S9 AND (S20 OR S25 OR S27) AND S32
S35	15	RD (unique items)
S36	117578	LIPOSOME? ?
S37	111330	INFLUENZA
S38	17	S9 AND S11 AND S32
S39	7	S38 NOT PY>1995
S40	7	RD (unique items)
S41	417418	S20 OR S25 OR S27
S42	4283	S9 AND S41
S43	1357	S42 AND S36
S44	256	S43 AND S37
S45	2	S44 AND S25

?



US, 836, 576

2/23/00